SABCS 2022

SABCS 2022
December 06-10, 2022
San Antonio, TX

San Antonio Breast Cancer Symposium 2022.

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (4)

    Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in HR+/HER2- metastatic breast cancer

    • Author(s): Tolaney, SM
    • trodelvy
    • Oncology

    A phase 2, randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triplenegative breast cancer (TiP)

    • Author(s): Rainey, N
    • magrolimab
    • Oncology

    Effect of sacituzumab govitecan vs chemotherapy in HR+/HER2- metastatic breast cancer: patient-reported outcomes from the TROPiCS-02 trial

    • Author(s): Marme, F
    • trodelvy
    • Oncology

    Sacituzumab Govitecan vs Treatment of Physician's Choice: Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients With HR+/HER2- Metatatic Breast Cancer

    • Author(s): Rugo, HS
    • trodelvy
    • Oncology